Abstract
An all-oral therapy for treating hepatitis C (HCV) is now available for the most common genotypes although interferon-based therapy is still recommended for interferon-eligible patients with HCV genotype 1. For most patients, a prior history of treatment or presence of cirrhosis does not appear to significantly impact eradication rates with direct acting antivirals (DAA). The promising results from the numerous clinical trials of DAA's for HCV together with their tolerability represent a tremendous advance in our management of this disease, particularly as treatment is often well-tolerated, associated with few side effects and significantly shortened in duration. We will review several of the peer-reviewed landmark studies of DAA's for the treatment HCV and conclude with an expert commentary and five year view.
| Original language | English |
|---|---|
| Pages (from-to) | 499-505 |
| Number of pages | 7 |
| Journal | Expert Review of Clinical Pharmacology |
| Volume | 7 |
| Issue number | 4 |
| DOIs | |
| State | Published - 2014 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Pharmacology (medical)
- Pharmacology, Toxicology and Pharmaceutics(all)
- Medicine(all)
Cite this
Antiviral therapy for chronic hepatitis C in 2014. / Nookathota, Manogna; Mukherjee, Sandeep.
In: Expert Review of Clinical Pharmacology, Vol. 7, No. 4, 2014, p. 499-505.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Antiviral therapy for chronic hepatitis C in 2014
AU - Nookathota, Manogna
AU - Mukherjee, Sandeep
PY - 2014
Y1 - 2014
N2 - An all-oral therapy for treating hepatitis C (HCV) is now available for the most common genotypes although interferon-based therapy is still recommended for interferon-eligible patients with HCV genotype 1. For most patients, a prior history of treatment or presence of cirrhosis does not appear to significantly impact eradication rates with direct acting antivirals (DAA). The promising results from the numerous clinical trials of DAA's for HCV together with their tolerability represent a tremendous advance in our management of this disease, particularly as treatment is often well-tolerated, associated with few side effects and significantly shortened in duration. We will review several of the peer-reviewed landmark studies of DAA's for the treatment HCV and conclude with an expert commentary and five year view.
AB - An all-oral therapy for treating hepatitis C (HCV) is now available for the most common genotypes although interferon-based therapy is still recommended for interferon-eligible patients with HCV genotype 1. For most patients, a prior history of treatment or presence of cirrhosis does not appear to significantly impact eradication rates with direct acting antivirals (DAA). The promising results from the numerous clinical trials of DAA's for HCV together with their tolerability represent a tremendous advance in our management of this disease, particularly as treatment is often well-tolerated, associated with few side effects and significantly shortened in duration. We will review several of the peer-reviewed landmark studies of DAA's for the treatment HCV and conclude with an expert commentary and five year view.
UR - http://www.scopus.com/inward/record.url?scp=84903186698&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84903186698&partnerID=8YFLogxK
U2 - 10.1586/17512433.2014.915737
DO - 10.1586/17512433.2014.915737
M3 - Review article
C2 - 24939471
AN - SCOPUS:84903186698
VL - 7
SP - 499
EP - 505
JO - Expert Review of Clinical Pharmacology
JF - Expert Review of Clinical Pharmacology
SN - 1751-2433
IS - 4
ER -